Publication | Closed Access

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

Additional TherapiesParkinson DiseaseClinical NeurologyAdagio StudyClinical NeuroscienceRehabilitationNeurologyNeuroscienceDelayed-start TrialMedicine